Tubulis announced the second and final closing of its Series C financing round, bringing the total raised to €344 million ($401 million). The round included new investors Fidelity Management & Research Company, Janus Henderson Investors, and Blackstone Multi-Asset Investing. These groups join a syndicate led by Venrock Healthcare Capital Partners, alongside new investors Wellington Management and Ascenta Capital. Existing investors continuing their support include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT, and Seventure Partners.
The proceeds from this Series C will enable Tubulis to accelerate the clinical development of its lead antibody-drug conjugate (ADC) candidate, TUB-040. The funding will also enable the company to expand into earlier treatment lines for ovarian cancer, explore new solid tumor indications, and launch pivotal trials following the presentation of positive early clinical data at the European Society of Medical Oncology (ESMO) Congress 2025 in Berlin.
TUB-040, the company’s lead ADC candidate, demonstrated promising results in the NAPISTAR1-01 Phase I/IIa study (NCT06303505) for platinum-resistant high-grade serous ovarian cancer. The data validated Tubulis’ proprietary Tubutecan technology, showing a differentiated clinical profile characterized by anti-tumor activity at low doses, a wide therapeutic window, and favorable safety and tolerability outcomes.
Beyond TUB-040, Tubulis plans to advance its clinical-stage ADC program TUB-030, as well as multiple preclinical programs. The company will also continue to enhance its proprietary ADC platform technologies to support novel applications and improve drug delivery.
Founded to develop next-generation ADCs with superior stability and efficacy, Tubulis has established a leadership position in the field by combining innovative bioconjugation technologies with a focus on durable, targeted tumor treatment. Its growing pipeline, led by TUB-040 and TUB-030, aims to address unmet needs in high-demand solid tumor indications.
KEY QUOTE:
“We are expanding our syndicate with prestigious investors who all have significant track-records and a strategic long-term focus. The combined group of funds enables us to accelerate our clinical development plans and further expand our global footprint. We are now in a strong position to deliver on our goal – realizing the full potential of the ADC drug class for more patients.”
Dr. Dominik Schumacher, Chief Executive Officer and Co-founder of Tubulis
